Abstract Number: 2539 • 2013 ACR/ARHP Annual Meeting
The Reliability Of a Novel Automated System For ANA Immunofluorescence Analysis In Daily Clinical Practice
Background/Purpose: Recently, automated interpretation (AI) systems for anti-nuclear antibody (ANA) analysis have been introduced based on assessment of indirect immunofluorescence (IIF) patterns. However, the reliability…Abstract Number: 2540 • 2013 ACR/ARHP Annual Meeting
Serum Mercury Level and Disease Activity Of Systemic Lupus Erythematosus (SLE): A Case-Control Study
Background/Purpose: Environmental contamination with mercury (Hg) is linked to autoimmune diseases. Exposure to low-dose non-organic mercury has been reported to exacerbate murine SLE. The aim of…Abstract Number: 2542 • 2013 ACR/ARHP Annual Meeting
Validation Of The Revised Selena Flare Index In Systemic Lupus Erythematosus
Background/Purpose: The SELENA flare index (SFI) has been used in clinical and clinical trial settings since 2005 (1), but has the limitation that it classifies…Abstract Number: 2543 • 2013 ACR/ARHP Annual Meeting
Patients’ Perception Of Their Lupus Disease Activity, But Not Overall Health, Correlates With Physician Assessments
Background/Purpose: The Physician Global Assessment represents the average assessment of a patient’s disease activity based on physical examination and laboratory data while the Patient Global…Abstract Number: 2544 • 2013 ACR/ARHP Annual Meeting
Serum Mediated Phagocytosis Of Necrotic Material By Polymorphonuclear Leukocytes May Be Used As a Tool To Predict Clinical Manifestations In Systemic Lupus Erythematosus
Background/Purpose: Polymorphonuclear (PMNs) leukocytes with engulfed necrotic cell material (NCM), as formerly used in the LE-cell test, are frequently seen in SLE and associated to…Abstract Number: 2545 • 2013 ACR/ARHP Annual Meeting
Active Systemic Lupus Erythematosus: Cytokines and Soluble Tumor Necrosis Factor Receptors Response To Moderate/Intense Exercise
Background/Purpose: Systemic lupus erythematosus (SLE) is a rheumatic autoimmune condition characterized by altered lipoprotein profile, physical dysfunction and increased risk of cardiovascular disease. Exercise is,…Abstract Number: 2546 • 2013 ACR/ARHP Annual Meeting
Anti-Nucleosome Antibodies As a Predictor Factor For Relapses In Clinically Quiescent Systemic Lupus Erythematosus: Results Of a Prospective Cohort Study
Background/Purpose: A significant number of studies have identified a correlation between anti-nucleosome antibodies (AN-ab) and disease activity in SLE; nevertheless, there is a lack of…Abstract Number: 2547 • 2013 ACR/ARHP Annual Meeting
Anti-Ribosomal P Antibody Has a Protective Role In The Development Of Chronic Kidney Disease In Patients With Lupus Nephritis
Background/Purpose: Anti-ribosomal P antibody (anti-P) in patients with systemic lupus erythematosus (SLE) is associated with neuropsychiatric manifestation. Of interest, recent studies have suggested that anti-P…Abstract Number: 2548 • 2013 ACR/ARHP Annual Meeting
Assessment Of Worsening In Lupus Clinical Trials: Do The Endpoints Reflect Medical Judgement?
Background/Purpose: Discrimination between treatment and placebo is problematic in lupus trials. Recently, composite endpoints have evolved which define response by both improvement in baseline findings…Abstract Number: 2549 • 2013 ACR/ARHP Annual Meeting
Can Biomarkers Provide An Objective Standard Against Which To Assess Lupus Clinical Endpoint Measures?
Background/Purpose: Despite the heterogeneity of SLE, specific pathways of immune dysregulation characterize significant subsets of patients. We examined cytokines reflecting IL6-TH17 pathology in lupus as…Abstract Number: 2550 • 2013 ACR/ARHP Annual Meeting
Predictive Markers Of Preeclampsia During Pregnancy In Patients With Systemic Erithematosus LUPUS and / Or Antiphospholipid Syndrome
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have an increased risk of preeclampsia (PE), which can be confused with lupus nephritis. Our objective was to…Abstract Number: 2551 • 2013 ACR/ARHP Annual Meeting
Pharmacodynamics and Predictive Biomarkers In Patients Treated With Atacicept: Data From The APRIL-SLE Trial
Background/Purpose: Atacicept is a fusion protein that inhibits B cell stimulating factors BLyS and APRIL. We examined the pharmacodynamic (PD) effects of atacicept in patients…Abstract Number: 2523 • 2013 ACR/ARHP Annual Meeting
Inflammatory Arthritis Activity During Pregnancy In Systemic Lupus Erythematosus
Background/Purpose: While overall SLE disease and lupus nephritis activity during pregnancy have been studied, the activity of inflammatory arthritis during SLE pregnancy has not been…Abstract Number: 2512 • 2013 ACR/ARHP Annual Meeting
Smoking Is Associated With More Severe Skin Disease In Subjects With Moderate To Severe Systemic Lupus Erythematosus (SLE)
Background/Purpose: The influence of smoking on the severity of cutaneous manifestations in adults with moderate to severe SLE was assessed in an ongoing international, multi-center,…Abstract Number: 2513 • 2013 ACR/ARHP Annual Meeting
Anti-Mullerian Hormone In Patients With Systemic Lupus Erythematosus
Background/Purpose: Systemic Lupus Erythematosus (SLE) frequently affects women in childbearing age; disease related factors and treatment can interfere with ovarian function. Anti-Mullerian-hormone (AMH) levels are…
ACR Meeting Abstracts